NZ578816A - Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation - Google Patents
Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiationInfo
- Publication number
- NZ578816A NZ578816A NZ578816A NZ57881608A NZ578816A NZ 578816 A NZ578816 A NZ 578816A NZ 578816 A NZ578816 A NZ 578816A NZ 57881608 A NZ57881608 A NZ 57881608A NZ 578816 A NZ578816 A NZ 578816A
- Authority
- NZ
- New Zealand
- Prior art keywords
- sema6a
- seq
- polypeptide
- disease
- vector
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89899207P | 2007-02-02 | 2007-02-02 | |
| PCT/US2008/001444 WO2008097503A2 (en) | 2007-02-02 | 2008-02-04 | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ578816A true NZ578816A (en) | 2012-06-29 |
Family
ID=39682299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ578816A NZ578816A (en) | 2007-02-02 | 2008-02-04 | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9107884B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2114433B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5492567B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090123873A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101631559A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008214337B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0806849A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2677228C (cg-RX-API-DMAC7.html) |
| EA (1) | EA017403B1 (cg-RX-API-DMAC7.html) |
| GE (1) | GEP20135853B (cg-RX-API-DMAC7.html) |
| IL (1) | IL200123A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009008178A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ578816A (cg-RX-API-DMAC7.html) |
| SG (1) | SG178744A1 (cg-RX-API-DMAC7.html) |
| UA (1) | UA99452C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008097503A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200905379B (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871205B2 (en) * | 2009-11-25 | 2014-10-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
| FI3590960T3 (fi) * | 2012-02-29 | 2023-04-25 | Takeda Pharmaceuticals Co | Perifeeristen hermojen IgG-stimuloitu remyelinaatio |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| KR20230145206A (ko) | 2014-11-14 | 2023-10-17 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
| CN114717264A (zh) | 2014-11-14 | 2022-07-08 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| EP3262064A1 (en) * | 2015-02-23 | 2018-01-03 | Seagull Therapeutics SAS | Non-natural semaphorins 3 and their medical use |
| ES2969187T3 (es) * | 2015-06-29 | 2024-05-16 | Univ British Columbia | Tratamientos, métodos y usos de la proteína de fusión B1SP |
| US10584337B2 (en) | 2016-05-18 | 2020-03-10 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| JP7109040B2 (ja) * | 2016-07-25 | 2022-07-29 | 国立大学法人金沢大学 | 線維化抑制剤 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| CN109536506B (zh) * | 2018-12-10 | 2022-03-22 | 潍坊科技学院 | 一种调控日本沼虾生长发育的类胰岛素受体基因及其应用 |
| WO2025105734A1 (ko) * | 2023-11-15 | 2025-05-22 | 주식회사 카인사이언스 | 탈수초 질환 치료용 펩타이드 및 이의 용도 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773319A (en) | 1971-12-16 | 1973-11-20 | Fabcor Ind Inc | Corrugated sheet inverting machine |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| ES2150428T3 (es) | 1987-04-27 | 2000-12-01 | Unilever Nv | Ensayos de union especifica. |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| US5219837A (en) * | 1990-06-21 | 1993-06-15 | Trustees Of The University Of Pennsylvania | Method of stimulating myelination of cells |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
| CA2149326C (en) | 1992-11-13 | 2007-04-17 | Mitchell E. Reff | Fully impaired consensus kozak sequences for mammalian expression |
| US6068829A (en) | 1995-09-11 | 2000-05-30 | The Burnham Institute | Method of identifying molecules that home to a selected organ in vivo |
| RO120148B1 (ro) | 1997-03-14 | 2005-09-30 | Idec Pharmaceuticals Corporation | Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere |
| EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
| CA2487939A1 (en) * | 2002-05-30 | 2003-12-11 | Curagen Corporation | Semaphorin-like proteins and methods of using same |
-
2008
- 2008-02-04 EA EA200901067A patent/EA017403B1/ru not_active IP Right Cessation
- 2008-02-04 CN CN200880003680A patent/CN101631559A/zh not_active Withdrawn
- 2008-02-04 AU AU2008214337A patent/AU2008214337B2/en not_active Ceased
- 2008-02-04 WO PCT/US2008/001444 patent/WO2008097503A2/en not_active Ceased
- 2008-02-04 US US12/525,514 patent/US9107884B2/en active Active
- 2008-02-04 SG SG2012007456A patent/SG178744A1/en unknown
- 2008-02-04 MX MX2009008178A patent/MX2009008178A/es active IP Right Grant
- 2008-02-04 EP EP08713389.8A patent/EP2114433B1/en active Active
- 2008-02-04 BR BRPI0806849-6A patent/BRPI0806849A2/pt not_active Application Discontinuation
- 2008-02-04 NZ NZ578816A patent/NZ578816A/en not_active IP Right Cessation
- 2008-02-04 JP JP2009548329A patent/JP5492567B2/ja active Active
- 2008-02-04 UA UAA200908176A patent/UA99452C2/ru unknown
- 2008-02-04 GE GEAP200811447A patent/GEP20135853B/en unknown
- 2008-02-04 CA CA2677228A patent/CA2677228C/en active Active
- 2008-02-04 KR KR1020097018262A patent/KR20090123873A/ko not_active Ceased
-
2009
- 2009-07-28 IL IL200123A patent/IL200123A/en active IP Right Grant
- 2009-07-31 ZA ZA2009/05379A patent/ZA200905379B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG178744A1 (en) | 2012-03-29 |
| EA200901067A1 (ru) | 2010-02-26 |
| MX2009008178A (es) | 2009-10-26 |
| KR20090123873A (ko) | 2009-12-02 |
| GEP20135853B (en) | 2013-06-25 |
| JP2010518007A (ja) | 2010-05-27 |
| AU2008214337A1 (en) | 2008-08-14 |
| US20100189713A1 (en) | 2010-07-29 |
| IL200123A0 (en) | 2010-04-15 |
| ZA200905379B (en) | 2014-01-29 |
| CN101631559A (zh) | 2010-01-20 |
| UA99452C2 (ru) | 2012-08-27 |
| IL200123A (en) | 2013-05-30 |
| US9107884B2 (en) | 2015-08-18 |
| WO2008097503A8 (en) | 2009-11-05 |
| EP2114433B1 (en) | 2014-04-09 |
| CA2677228A1 (en) | 2008-08-14 |
| EP2114433A2 (en) | 2009-11-11 |
| AU2008214337B2 (en) | 2012-07-05 |
| WO2008097503A2 (en) | 2008-08-14 |
| EA017403B1 (ru) | 2012-12-28 |
| WO2008097503A3 (en) | 2008-12-24 |
| JP5492567B2 (ja) | 2014-05-14 |
| BRPI0806849A2 (pt) | 2015-06-23 |
| CA2677228C (en) | 2015-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2677228C (en) | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation | |
| US20200297800A1 (en) | Use of lingo-4 antagonists in the treatment of conditions involving demyelination | |
| US9068992B2 (en) | Screening methods for identifying Sp35 antagonists | |
| US20110052500A1 (en) | TAJ in Neuronal Function | |
| US20090175846A1 (en) | Oligodendrocyte-Myelin Glycoprotein Compositions and Methods of Use Thereof | |
| WO2007098283A2 (en) | Use of antagonists of maif receptor complex molecules and neurotrophic factors for treatment of neurological diseases and disorders | |
| EP2543384A2 (en) | Treatment of conditions involving demyelination | |
| EP2510934A1 (en) | Methods for promoting neurite outgrowth and survival of dopaminergic neurons | |
| HK1134254A (en) | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation | |
| HK1134254B (en) | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation | |
| US20090111753A1 (en) | Nogo-A Polypeptide Fragments, Variant Nogo Receptor-1 Polypeptides, and Uses Thereof | |
| HK1103978B (en) | Treatment of conditions involving demyelination | |
| HK1157572A (en) | Influence of taj in the neuronal functions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 FEB 2018 BY COMPUTER PACKAGES INC Effective date: 20140909 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2019 BY ENVOY INTERNATIONAL LIMITED Effective date: 20180116 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2020 BY RENEWALS TEAM Effective date: 20181222 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2021 BY CPA GLOBAL Effective date: 20200117 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2022 BY CPA GLOBAL Effective date: 20210114 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2023 BY CPA GLOBAL Effective date: 20211223 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2024 BY ANAQUA SERVICES Effective date: 20230120 |
|
| LAPS | Patent lapsed |